Morgan Stanley raised the firm’s price target on Regenxbio (RGNX) to $25 from $24 and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- REGENXBIO Reports Q3 2025 Financial and Operational Progress
- Regenxbio reports Q3 EPS ($1.20), consensus ($1.30)
- Regenxbio expects cash, equivalents to fund operations into early 2027
- FDA’s ‘surprising’ uniQure reversal drags down Biohaven
- RegenXBio’s Strong Position in Biotechnology Justifies Buy Rating Amid Gene Therapy Uncertainties